Pharma Products Face Uncertain Future In Boston Scientific's 'Logical' £3.3bn Bid For UK's BTG
Executive Summary
Boston Scientific CEO says US group has been tracking UK-based BTG "for more than two years" and that interventional medicine is a key attraction.
You may also be interested in...
SERB Pays $800m For Boston Scientific Specialty Pharma Business
The sale of BTG Specialty Pharmaceuticals to two affiliates of European specialty firm SERB leaves Boston Scientific with BTG’s interventional oncology and vascular products.
Carrick Targets Ovarian Cancer With BTG Deal, Entices Celgene’s Former Top Deal Maker
In a busy week, Carrick Therapeutics has added to its oncology pipeline, as well as bringing in Celgene deal maker George Golumbeski.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.